Monoclonal Antibodies in Neuro-Oncology

Citation
Lampson, Lois A. 2011. Monoclonal antibodies in neuro-oncology. mAbs 3(2): 153-160.

Published Version
doi:10.4161/mabs.3.2.14239

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10330728

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Monoclonal antibodies in neuro-oncology
Getting past the blood-brain barrier

Lois A. Lampson
Department of Neurosurgery; Brigham & Women's Hospital and Harvard Medical School; Boston, MA USA

Key words: monoclonal antibody, brain tumor, immunotherapy, glioma, primary central nervous system lymphoma, brain metastases, bevacizumab, rituximab, trastuzumab

Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; BBB, blood-brain barrier; CDC, complement-dependent cytotoxicity; CNS, central nervous system; CSF, cerebrospinal fluid; ECM, extracellular matrix; GBM, glioblastoma multiforme; MS, multiple sclerosis; PCNSL, primary central nervous system lymphoma; PVS, perivascular space; VEGF, vascular endothelial growth factor

Monoclonal antibodies (mAbs) are used with increasing success against many tumors, but for brain tumors the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is more complex. The BBB is closest to normal at micro-tumor sites; its properties and importance change as the tumor grows. In this review, evolving insight into the role of the BBB is balanced against other factors that affect efficacy or interpretation when mAbs are used against brain tumor targets. As specific examples, glioblastoma multiforme (GBM), primary central nervous system lymphoma (PCNSL) and blood-borne metastases from breast cancer are discussed in the context of treatment, respectively, with the mAbs bevacizumab, rituximab and trastuzumab, each of which is already widely used against tumors outside the brain. It is suggested that success against brain tumors will require getting past the BBB in two senses: physically, to better attack brain tumor targets, and conceptually, to give equal attention to problems that are shared with other tumor sites.

Introduction
An early hope for monoclonal antibodies (mAbs) was that they would serve as tumor-specific magic bullets in two ways. As bullets, they would move through the blood to reach and attack tumor targets. The exquisite specificity of a single antibody would provide the magic. Experience with tumors outside the brain has begun to justify this hope. Among the best-studied examples, the mAbs trastuzumab (Herceptin®), rituximab (Rituxan®) and bevacizumab (Avastin®), are now approved as part of the standard therapy for appropriate forms of breast cancer,® 1-4 B-cell lymphoma,® 5,6 and colorectal cancer, respectively, as well as other types of cancer.® 7,8

Over time, we have become more sophisticated about both the bullet and its magic. For tumors outside the brain, long-term remissions can indeed be achieved, but not all eligible patients respond, responses may be short-lived and side effects can be limiting.1-8 Many of the evolving insights and adaptations apply very generally to many different therapies or to tumors at many sites. Additional insights apply and new insights are still needed for tumor in the brain.

In applying mAb therapy to brain tumors, both expectations and interpretation are colored by awareness of the blood-brain barrier (BBB). A striking example is seen when tumors in the bodies of breast cancer patients respond to systemic mAb treatment, but then metastases appear in the brain.9,10 The reason most often suggested for this phenomenon is that the BBB must be blocking access to the brain metastases, making the brain a sanctuary site; however, the full explanation must be more complex. Accumulating experience suggests that systemic antibody can be beneficial for patients with brain metastases or with other targets in the brain. How can this be the case if access is blocked by the BBB? If access is not in fact limiting, how is late failure in the brain to be explained, especially when it occurs in parallel with tumor control at other sites?9-11

The questions above set the context for this review. To address them, brain tumors (the target), antibodies (the magic), how antibodies attack tumor (the bullet) and how they reach it (the barrier) are reviewed in turn. With this as background, practical experience with mAbs for brain tumor targets is re-visited (the findings) and ways to go forward are suggested (the future).

The Target: Tumor in the Brain
Three tumor types. Three brain tumor types, each coupled to a mAb that has already been used extensively outside the brain, are discussed below (Table 1). Together, these antibody/target
As such, GBM has been the focus of much work with mAbs, as (GBM), is the most common and aggressive type in adults. The tumor mass and the infiltrative component present differ-
vantly in pre-clinical work. Experience with bevacizumab (Avastin) humanized VEGF No

Table 1. Tumor/antibody combinations emphasized in the text

| Brain tumors discussed | Antibodies discussed | Target antigens |
|------------------------|----------------------|-----------------|
| General type | Specific example | Name | How modified | Name | Unique to tumor? |
| glioma | GBM* | bevacizumab (Avastin) | humanized | VEGF* | No |
| lymphoma | PCNSLb | rituximab (Rituxan) | chimeric | CD20d | No |
| metastatic | breast cancer | trastuzumab (Herceptin) | humanized | Her2e | No |

*GBM, glioblastoma multiforme; bPCNSL, primary central nervous system lymphoma; cVEGF, vascular endothelial growth factor; dCD20, common B-cell antigen; eHer2, human epidermal growth factor receptor 2

The challenges of treating brain tumor targets are well illustrated by experience with the mAbs listed in Table 1. Before turning to the clinical findings, it is useful to briefly review properties of the mAbs themselves.

tumor, at any site, as well as practical difficulties in interpretation for targets in the brain.

Metastatic. Blood-borne metastases from other organs are many-fold more frequent than primary brain tumors; the most common sources are tumors of the lung and breast. For many tumors of origin, parenchymal metastases remain (at least initially) in the perivascular space (PVS); the infiltrative growth that is characteristic of glial brain tumors or PCNSL is not seen. Another difference from primary brain tumors is that, when patients appear to benefit from systemic mAb, the site of attack can be questioned; efficacy may reflect better control of systemic tumor, rather than of tumor in the brain itself. Interpretation of apparent benefit from systemic trastuzumab, used against human epidermal growth factor receptor 2 (Her2)-overexpressing metastatic breast cancer, suggests this possibility.

Some common features. Need for new therapies. For each of the tumors described above, new therapies are needed. With current therapy, the median survival after diagnosis of GBM is less than 15 months; survival can be similar or even shorter after diagnosis of brain metastases, or after relapse of PCNSL.

Micro-tumor targets. Microscopic tumor (or micro-tumor), tumor too small to be readily imaged by conventional methods, is an important component of many brain tumors, including those stressed here. For GBM or other glial brain tumors, infiltrative tumor is known to remain after a main tumor mass has been removed. PCNSL normally appears as a diffuse B-cell lymphoma and blood-borne tumor from other organs first enters the brain as micro-metastases.

For the many cases where it is known that micro-tumor is likely to be present somewhere in the brain, but not exactly where, localized therapies are not appropriate. This increases interest in agents such as mAbs that are less inherently toxic than the conventional therapies, and so safer for widespread delivery. For tumor outside the brain, a complementary attraction is that most therapies are thought most likely to succeed against micro-tumor, as opposed to larger masses. A confounding factor in the brain is that the BBB is closest to normal, and therefore most effective at blocking antibody access, at micro-tumor sites. A related problem is that, although the importance of brain micro-tumor is widely acknowledged, it is rarely targeted explicitly in pre-clinical work.

The challenges of treating brain tumor targets are well illustrated by experience with the mAbs listed in Table 1. Before turning to the clinical findings, it is useful to briefly review properties of the mAbs themselves.
The Magic: What Tumor-Specific Can Mean

Although antibody specificity is indeed exquisite,29 few determinants are limited to tumor cells (Fig. 2).24,30 Fortunately, shared molecules can serve as practical tumor targets and this is true for each molecule targeted by the mAbs in Table 1.

Each B-cell lymphoma expresses a unique idiotype, and this may well be the target of choice in the long term.31 Rituximab, in contrast, recognizes a common B-cell antigen, CD20, that is expressed by both normal and neoplastic B cells. At present, the advantage of rituximab is that it can be used for many different patients, coupled to the fact that the depletion of normal B cells can be tolerated because existing antibody and antibody-forming plasma cells are spared, other protective mechanisms remain active and B cells are eventually replaced.32,33

Although more restricted antigens are known for GBM,34 there has been enormous interest in using bevacizumab to target vascular endothelial growth factor (VEGF), which promotes angiogenesis for tumors, but also in normal wound healing.35 Trastuzumab targets Her2, which is overexpressed in many breast cancers, but also expressed by normal cells.1,24,36 In practice, each of these three mAbs has been used successfully against tumor outside the brain1 and, increasingly, is being used against brain tumor targets.

Although targets need not be limited to strict tumor-specific antigens, cross-reactions may cause problems for individual patients. More generally, the problem of resistance is increasingly acknowledged.2,4,12,37,38 For any given mAb, a tumor cell can escape attack at many levels, from its expression of the target determinant, to its susceptibility to the final effector mechanism.12,31,37-39 Probing the basis of resistance is complicated by uncertainty as to which, among many possibilities, are the most important effector mechanisms for a given mAb, tumor and site.

The Bullet: What Antibodies Can Do

Antibodies can lead to death or arrest of a tumor target in a great and growing variety of ways, with new antibody-mediated functions still being identified. Antibodies can directly block activity of a target molecule simply by binding to it, through the antibody variable region,36,40 while additional functions are brought to bear if the constant (Fc) region is engaged. The benefits of Fc binding to elements of the complement cascade or cell-bound Fc receptors are well known.36,40 More recently appreciated is that another kind of Fc receptor, FcRn, binds to an antibody in a way that protects it from degradation. This contributes to the prolonged serum half-life of an antibody, as compared to that of most other proteins.36,41

An antibody need not attack tumor cells themselves. Bevacizumab, which is intended to block development of a tumor’s blood supply, is an example.35 Also, the antibody does not necessarily need to attack its target in the brain. Bloodborne tumor or other targets may be attacked before they reach the brain. Complexes between an antibody and its target antigen can stimulate the patient’s own immune response or mAbs can modulate an ongoing response.30,38,42 Complementing these spontaneous activities, additional effector mechanisms come into play when mAbs are coupled to agents, such as radionuclides or toxins,24,40 or larger molecules or particles (liposomes, nanoparticles),24,43-45 so that the mAb serves a targeting function and the other component provides (or adds to) the attack mechanism. The sequence of the antibody protein itself may be modified to alter target binding or constant region functions,42 or avoid having the antibody recognized as a foreign protein by the patient’s immune system. All three antibodies discussed here were modified to reduce such recognition (Table 1).40 The variety of possible effector mechanisms is multiplied as antibodies are used in combination with other agents or modalities.37 Of particular relevance for brain tumor, radiotherapy is thought to alter the BBB in ways that increase antibody access to tumor sites.23,44

Even where antibody-mediated therapy has been most successful, the key effector mechanisms are not yet known.2,6,32,35,36,38,40 Not only is there a wealth of possibilities, but the balance of effector functions may differ at different tumor sites.12 The frequent use of combination therapies and the potential long-term effects of previous treatments further increase the difficulty of defining the effect of a given antibody. There may also be uncertainty as to where an antibody exerts its effects, for example, whether metastatic tumor is attacked at its source, en route or at its final site. In the brain, interpretation is further impeded by the difficulty of directly analyzing the tumor site. These uncertainties, in turn, complicate interpretation of the role of the BBB.
The Barrier: How Entry to the Brain is Controlled

The ability of the BBB to block passive entry of therapeutics into the normal brain is well known; however, understanding of the BBB, even in the normal brain, is still evolving. The BBB is dynamic and can be manipulated; unfortunately, it is not the only impediment.

Entry to normal brain. What impedes entry. In the brain parenchyma, the anatomical BBB is formed by specialized tight junctions between the endothelial cells of cerebral micro-vessels, together with astrocyte endfeet that abut the endothelium, adjacent pericytes and a characteristic composition of the extracellular matrix (ECM). This anatomical barrier is complemented by a physiological barrier that includes reduced pinocytosis by the endothelial cells (as compared to other tissues), degradative enzymes and transporters that act as efflux pumps to actively return many kinds of molecules, including many drugs, to the blood. Other CNS compartments have variations of these properties, so that the brain environment remains controlled.

Entry to tumor sites. Not static. The BBB is dynamic, its properties specified and maintained by reciprocal interactions with adjacent cells. BBB properties change during development and other normal processes, as well as in the context of inflammation or other pathology, including tumor growth. The BBB may be essentially normal at micro-tumor sites; as the tumor grows, the BBB is progressively disrupted. Ultimately, tumor grows, the BBB is progressively disrupted. Not only impediment. When primary or metastatic brain tumors; rather, they can impede the distribution or activity of antibody or other therapy against solid tumor at any site.

The barrier, a role in removal of harmful antibody from the brain has been suggested, but the actual roles are not yet known. In other tissues, FcRn-mediated transport is bi-directional, and the predominant direction can be modified experimentally. It is intriguing to consider whether FcRn might also act to bring antibody into brain tumor sites—or might be exploited for that purpose.

Entry to tumor sites. Not static. The BBB is dynamic, its properties specified and maintained by reciprocal interactions with adjacent cells. BBB properties change during development and other normal processes, as well as in the context of inflammation or other pathology, including tumor growth. The BBB may be essentially normal at micro-tumor sites; as the tumor grows, the BBB is progressively disrupted. Ultimately, new vessels may be formed and the tumor itself modulates their properties. Indeed, for brain metastases, tumor-adjacent vessels may resemble abnormal versions of vessels in the tissue of origin, rather than brain barrier vessels.

Not the only impediment. When primary or metastatic brain tumor can be imaged by a contrasting-enhancing agent, typically gadolinium, the vessels must be at least leaky enough to permit the agent's extravasation. Unfortunately, this does not necessarily imply effective delivery of mAbs. Even in the normal brain, the distribution of a given molecule will vary with its size, shape, charge, composition (such as lipophilicity) and the extent to which it binds to blood components or tissue. As two examples of the relevance of these factors, antibodies are much larger than gadolinium and many drugs bind tightly to serum proteins. An important consequence is that the distribution of a contrast-enhancing agent does not necessarily reflect the distribution of therapeutic agents.

Tumor-associated vessels may be leaky, but are also tortuous and chaotic, so that, even if blood-borne molecules do leave the vessel, they may not be evenly distributed within the tumor. Factors such as an unfavorable pressure gradient and the nature of the extracellular matrix can impede the ability of therapeutics, including antibodies, to become well-distributed within a tumor mass, while the center of a large tumor can act as a sink. In GBM in particular, blood-borne agents will accumulate in the necrotic center, with its disrupted BBB, rather than at the infiltrative edge, where the BBB is more like that of normal brain. Properties of the tumor cell itself can further impede antibody binding or efficacy. Most of these factors are not unique to brain tumors; rather, they can impede the distribution or activity of antibody or other therapy against solid tumor at any site.

In the brain, interpretation of antibody levels is hampered by the difficulty of taking local measurements. Instead, the concentration of therapeutic agents is often followed by measuring levels in cerebrospinal fluid (CSF). This approach does not take into account anatomic and metabolic heterogeneity within the normal brain, and potential inaccuracy is additionally compounded by heterogeneity among tumor sites. Even at a single site, antibody access can change with time. As tumor either responds to therapy or continues to grow, the BBB itself, as well as the other impediments to antibody access, will change accordingly.

The Findings: Experience with Three Brain Tumor/Antibody Pairs

The topics discussed so far provide a context for reviewing clinical experience with mAbs in brain tumor therapy. Three of the best-studied antibody/target combinations (Table 1) illustrate specific details.

Bevacizumab and GBM. The original intention was that bevacizumab would bind VEGF and so attack the highly vascular main tumor mass indirectly, by depriving it of its blood supply. In practice, the antibody does affect tumor blood vessels, reducing their leakiness and other abnormal properties. Benefits of this vessel normalization include reduced edema and intracranial pressure, which permits reduced steroid use, and perhaps also protection against radiation necrosis.

The effect on tumor growth per se has been hard to interpret. Because it affects blood vessels, bevacizumab also affects extravasation of the contrast agents used to image a tumor mass. In this situation, improvement in the radiographic image can be misleading: It may simply reflect reduced extravasation of the contrast agent rather than tumor control.

The disseminated components of GBM present complementary challenges. Individual infiltrative cells do not depend on angiogenesis. On the contrary, it has been suggested that, in response to bevacizumab, infiltrative growth, as well as other forms of parenchymal invasion, may even be increased. The effect of bevacizumab on drug delivery is also complex.
Normalizing the vessels may improve distribution of blood-borne agents within a tumor mass, but may also impede their extravasation, by restoring the BBB. More general factors, not limited to brain tumors, also impede interpretation of an antibody’s effects. Many reports of brain tumor findings concern small studies and many depend on historical controls. Moreover, the antibody is normally part of a complex regimen, including surgery, radiation and chemotherapy, and is often given in combination with (further) chemotherapy. All these factors make it hard to define the effect of the antibody itself on tumor growth. Other questions concern response criteria. How to weigh overall survival as opposed to progression-free survival; the possibility that high statistical significance may reflect relatively small quantitative differences in the response and the possibility that a responsive subgroup may go undetected are concerns that apply to all tumors. When there is apparent benefit, the same limitations seen in other contexts apply: as with other tumors, benefits of bevacizumab for GBM patients are transient. As happens after treatment with other new therapies, GBM normally recurs.

**Rituximab and PCNSL.** Rituximab targets the common B-cell marker CD20. Outside the brain, it shows efficacy in patients with different kinds of B-cell lymphoma. In the brain, its specificity is appropriate for PCNSL, which is typically a B-cell lymphoma. On the other hand, the BBB is likely to block antibody access to sites of infiltrative tumor, and this is also typical of PCNSL. This suggests that full efficacy may require actively delivering antibody across the BBB, because the BBB is often assumed to be important; however, its role depends upon a point that is often not explicitly discussed: Brain metastases often occur in parallel with tumor control at other sites. If the patient has responded to antibody therapy in the periphery, what can be the source of the newly-detected brain metastases? Two possibilities imply different roles for the BBB (Fig. 3).

**Model 1. New blood-borne tumor.** Late brain metastases may represent new blood-borne tumor from outside the brain, perhaps from known sites of apparently stable disease or from undetected, dormant tumor elsewhere. Eventually, this tumor begins to grow and provides a source of new blood-borne metastases. In this case, interpretation is aided by simpler treatments and well-controlled studies. Although rituximab shows efficacy in MS, the mechanism and sites of action are not known. In particular, because autoimmune B cells must enter the brain from the blood, efficacy does not necessarily reflect attack of targets in the brain.

**Trastuzumab and metastatic breast cancer.** The challenge of late brain metastases. As use of trastuzumab for Her2-overexpressing breast cancer became widespread, a troubling finding was an apparent increase in brain metastases. The BBB is often assumed to be important; however, its role depends upon a point that is often not explicitly discussed: Brain metastases often occur in parallel with tumor control at other sites. If the patient has responded to antibody therapy in the periphery, what can be the source of the newly-detected brain metastases? Two possibilities imply different roles for the BBB (Fig. 3).

**Model 1. New blood-borne tumor.** Late brain metastases may represent new blood-borne tumor from outside the brain, perhaps from known sites of apparently stable disease or from undetected, dormant tumor elsewhere. Eventually, this tumor begins to grow and provides a source of new blood-borne metastases. In this case, interpretation is aided by simpler treatments and well-controlled studies. Although rituximab shows efficacy in MS, the mechanism and sites of action are not known. In particular, because autoimmune B cells must enter the brain from the blood, efficacy does not necessarily reflect attack of targets in the brain.

**Model 2. Dormant tumor in the brain.** As an alternative scenario, tumor may have entered the brain long before it is detected and remained, undetected, as micro-metastases in a dormant state. As long as the BBB is close to normal, then...
contrast-enhancing agents, such as gadolinium, would not reveal this tumor and antibody therapeutics would not reach it (Fig. 3B). Once the tumor begins to grow, the BBB might initially be compromised enough for gadolinium, but not antibodies, to extravasate (Fig. 3C). The tumor could thus be detected radiographically, but not treated.

As the tumor continues to grow, the barrier will break down further and antibody may then extravasate (Fig. 3D). Therefore, if the same mAb treatment is continued, it may show efficacy eventually. Actively delivering the antibody across the BBB should allow for an earlier response. If the tumor grows too large before antibody is given, impediments besides the BBB will become increasingly important in blocking distribution of the antibody, even if it does leave the vessel (Fig. 3E).

The ability of systemic antibody to help control brain metastases would thus vary with the tumor’s current site (that is, whether or not it was already in the brain) and size, as depicted in Figure 3 as idealized examples. Brain metastases are heterogeneous, even within an individual, and may differ in the time of entry to the brain, susceptibility to the antibody in question and BBB status; moreover, each of these factors can change with time. Even with these caveats, the models compared above can help to interpret clinical findings, especially partial or disappointing responses.

In practice. Several authors have suggested that systemic antibody should be continued after brain metastases are detected in breast cancer patients and evidence of benefit has been reported. Interpretation is complicated by the same factors discussed above: Many studies are small or anecdotal and multiple modalities or agents may be involved. When there is apparent benefit, the key sites are not known. As many authors discuss, benefit from systemic antibody may simply reflect better control of systemic disease; it does not necessarily reflect direct attack of tumor within the brain itself. In practice, the potential for direct attack is likely to vary among different metastases and to change with time (Fig. 3).

Summary of clinical experience. There is evidence that systemic mAb treatment can benefit patients with brain tumors or other CNS pathology. The nature and site of antibody activity are less clear. The extent to which antibody enters—and acts on—tumor sites within the brain itself is not known. A conservative interpretation is that bevacizumab primarily reduces edema, and rituximab and trastuzumab act primarily on systemic targets. The complexity of tumor therapy, difficulty of direct local measurements, limitations of clinical trials and drawbacks of preclinical models all complicate interpretation of clinical results. Regardless of whether the antibody acted in the brain or elsewhere, an increase in overall or progression-free survival, or simply an improved quality of life, are certain of benefit to brain tumor patients. The goals for the future are, as for all tumors, to increase the benefit and reduce the cost of the therapeutics.

Related topics. The text has emphasized disseminated tumor within the brain, for which systemic delivery of mAbs is especially relevant. The focus has been on the role of the BBB, rather than specific strategies to overcome it, or cases, such as meningeval tumor, where other delivery routes are of special interest. The points raised should help to interpret findings for a variety of delivery strategies and tumor sites.

The Future

The natural evolution of mAb therapy for any tumor at any site is towards redundancy and refinement. Redundancy, in the sense that alternative targets are identified and alternative antibodies are prepared against promising targets, old or new. Refinement, in the sense that the new antibodies can be designed to solve specific problems: to avoid known cross-reactions or to work by means of alternative effector mechanisms. Refinement of another kind will come from combining therapies in more directed ways, in parallel with growing understanding of the underlying mechanisms of tumor growth, susceptibility and resistance. Combined targeting of a GBM tumor mass plus infiltrative tumor or existing brain metastases plus tumor that has not yet reached the brain are obvious examples. Improved clinical trial design will be important for all tumors, as more predictive pre-clinical models.

As for mAbs themselves, two parallel approaches are likely to be fruitful. One is to continue to refine the specificity and modifications of the antibody molecule itself. The other is to synthesize novel agents, using knowledge of antibody structure and function as a guide. Even as novel agents evolve, the whole antibody molecule still has great value. It has a long half-life and can mediate multiple functions, with new functions and uses still being identified. Indeed, the key mechanisms used by even the most successful antibodies in human patients are not yet established.

For all solid tumors, a complementary evolution of both understanding and technology is needed to improve delivery of therapeutics to larger tumor masses. For the brain, where delivery to micro-tumor is an equal challenge, clearer understanding of the nature and role of the BBB, complemented by improved methods for opening or bypassing it when necessary, have been long-standing goals. A third approach has received less attention: In other clinical contexts, sustained antibody synthesis occurs within the CNS. This too should be exploitable for brain tumor patients.

In the long run, how will mAb therapeutics benefit brain tumor patients? We may depend on antibody itself, a fragment or a synthetic alternative; the agent may be delivered passively or actively made within the brain; it may attack brain tumor directly or “only” targets outside the brain (such as blood-borne metastases or tumor vasculature); or even less directly, it may act to simulate or modify an endogenous response. Most likely, each variation will have its role. In planning and interpreting antibody therapy, the BBB has rightly commanded attention, yet its importance is balanced by that of more general problems of access and resistance. Going forward, a matching focus on challenges that are common to other agents, other tumors and other sites will be a complementary way of getting past the BBB.
Acknowledgements

I thank Cara Tripp for help with Figure 1 and comments on the text.

References

1. Bria E, Cuppone F, Formier N, Nistico C, Carlini P, Millella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231-9.
2. Nielsen DL, Andersson M, Kambly C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35:121-36.
3. Vlais GA, Alfonso SL, Stefano EJ, De Fendi LJ, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7:153.
4. Wiadakowich C, Ditth P, de Azambuja E, Awada A, Piccart-Gebhart M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 2008; 8:488-96.
5. Cheung MC, Haynes AE, Meyer RM, Stevens A, Inrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007; 33:161-76.
6. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14:6693-703.
7. Eksens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008; 44:2560-6.
8. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12:443-50.
9. Kaal EC, Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, Des 2007; 13:3545-58.
10. Yan T, Swanton C, Chua S, Aue A, Walsh G, Rosom A, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45:196-201.
11. Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumour? Int J Radiat Oncol Biol Phys 2007; 69:163-6.
12. Lampson LA. Targeted therapy for neuro-oncology: reviewing the menu. Drug Discov Today 2009; 14:185-91.
13. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici KR. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 2009; 29:5171-84.
14. Omuro AM, Faire S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007; 6:1909-19.
15. Verhooff JJ, van Tellingen O, Claas A, Stalpers LJ, van Linde ME, Rijkel DJ, et al. Concerns about anti-VEGF antibody treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2007; 88:331-40.
16. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008; 13:739-50.
17. Siu D. Cancer therapy using tumor-associated antigens to reduce side effects. Clin Exp Med 2009; 9:181-98.
18. Chung CH. Managing premedications and the risk for reactions to infusions of monoclonal antibody therapy. Oncologist 2008; 13:725-32.
19. Beckman RA, Weiner LM, Davis HM. Antibody construction in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170-9.
20. Lampson LA. New animal models to probe brain tumor biology, therapy and immunotherapy: advances and remaining concerns. J Neurooncol 2001; 53:275-87.
21. Lampson LA. Beyond new models: what else we need. In: Martines R, ed. Animal Models of Brain Tumors. Humana, In press.
22. Lampson L. Molecular bases of neuronal individuality: Lessons from anatomical and biochemical studies with monoclonal antibodies. In: Kennett R, ed al, Eds. Monoclonal Antibodies and Functional Cell Lines: Progress and Applications. Plenum Press 1984; 183-9.
23. Dougan M, Dranno F. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117.
24. Houver R, Levy R. Vaccines for lymphomas: idiootype vaccines and beyond. Blood Rev 2009; 23:1-32.
25. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008; 70:2252-60.
26. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, et al. Expression of nine tumour antigens including EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for circumventing resistance to anticancer monoclonal antibody therapy. Eur J Cancer 2009; 44:2350-6.
27. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2008; 25:2306-12.
28. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008; 10:166-77.
29. Doolittle ND, Najhke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, et al. Potential of chemo-immunotherapy and radiosensitization in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 2008; 48:1712-20.
30. Yilmaz M, Erttku I, Kilcioklu S, Pehlivan M, Okan V, Alpekln M, et al. Modified IDARAM chemotherapy regimen for intracranial central nervous system lymphoma: experience of three cases. Hematology 2008; 13:107-13.
31. Kim YY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBs J 2009; 276:4563-64.
32. Liu AK, Macy ME, Foteman KM. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009; 75:1148-54.
33. Tischkowitz M, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009; 94:63-8.
34. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-14.
35. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemothry with reduced whole-brain radiotherapy for newly diag- nosed primary CNS lymphoma. J Clin Oncol 2007; 25:4730-5.
59. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-88.
60. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev 2007; 26:635-43.
61. Bos PD, Zhang XH, Nalad C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459:1005-9.
62. Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 2008; 116:552-68.
63. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007; 85:311-7.
64. Bravo Marques JM. Treatment of brain metastases in patients with HER2+ breast cancer. Adv Ther 2009; 26:18-26.
65. Church DN, Bahl A, Jones A, Price CG. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab—a case report. J Neurooncol 2006; 79:289-92.
66. Metro G, Sperduer I, Russillo M, Milella M, Cognetti F, Fabi A. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007; 12:1467-9.
67. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009; 20:56-62.
68. Hong SJ, Kim JS, Chang JH, Kim KM, Kim SJ, Lee HW, et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009; 50:280-3.
69. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101:466-8.
70. Chow SC, Chang M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008; 3:11.
71. Dimitrov DS. Engineered CH2 domains (nanoantibodies). mAbs 2009; 1:26-8.
72. Lampson L, Tripp C. Antibody-secreting cells to deliver antibody against brain metastases. J Clinical Oncology 2007; 25:3047.